Hyperfine, Inc. is the groundbreaking medical device company that created Swoop, the world’s first FDA-cleared portable MRI system. Hyperfine designed Swoop to enable rapid diagnoses and treatment for every patient regardless of income, resources, or location, pushing the boundaries of conventional imaging technology and expanding patient access to life-saving care. The Swoop Portable MR Imaging System produces high-quality images at a lower magnetic field strength, allowing clinicians to quickly scan, diagnose, and treat patients in various clinical settings. Swoop can be wheeled directly to the patient’s bedside, plugged into a standard electrical wall outlet, and controlled by a tablet. Designed as a complementary system to conventional MRIs at a fraction of the cost, Swoop captures images in minutes, providing critical decision-making capabilities in emergency departments (ED), operating rooms (OR) outside the sterile field, and intensive care units (ICU), among others.
Company profile
Ticker
HYPR
Exchange
Website
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Medtronic • Varian Medical Systems • Conmed • Integer • Masimo • Natus Medical • LivaNova • GigCapital5 • Outset Medical • Fonar ...
Former names
HealthCor Catalio Acquisition Corp.
SEC CIK
Corporate docs
Subsidiaries
Hyperfine Operations, Inc. • Liminal Sciences, Inc. • Hyperfine Enterprise Ltd ...
HYPR stock data
Analyst ratings and price targets
Latest filings (excl ownership)
S-8
Registration of securities for employees
22 Mar 23
10-K
2022 FY
Annual report
22 Mar 23
8-K/A
Hyperfine, Inc. Reports Fourth Quarter and Full Year 2022 Financial Results
22 Mar 23
8-K
Hyperfine, Inc. Reports Fourth Quarter and Full Year 2022 Financial Results
21 Mar 23
8-K
Regulation FD Disclosure
10 Mar 23
8-K
Hyperfine, Inc. Swoop® Portable MR Imaging® System Receives CE Marking After Meeting Comprehensive New EU MDR Regulations
21 Feb 23
8-K
Hyperfine, Inc. Announces Brett Hale as New Chief Administrative Officer & Chief Financial Officer
8 Feb 23
EFFECT
Notice of effectiveness
31 Jan 23
424B3
Prospectus supplement
30 Jan 23
POS AM
Prospectus update (post-effective amendment)
24 Jan 23
Financial summary
Quarter (USD) | Dec 22 | Sep 22 | Jun 22 | Mar 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 118.24 mm | 118.24 mm | 118.24 mm | 118.24 mm | 118.24 mm | 118.24 mm |
Cash burn (monthly) | 5.17 mm | 6.08 mm | 4.54 mm | 6.16 mm | (no burn) | 2.21 mm |
Cash used (since last report) | 14.23 mm | 16.73 mm | 12.51 mm | 16.95 mm | n/a | 6.09 mm |
Cash remaining | 104.02 mm | 101.51 mm | 105.73 mm | 101.29 mm | n/a | 112.16 mm |
Runway (months of cash) | 20.1 | 16.7 | 23.3 | 16.5 | n/a | 50.7 |
Institutional ownership, Q4 2022
45.4% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 38 |
Opened positions | 11 |
Closed positions | 9 |
Increased positions | 7 |
Reduced positions | 7 |
13F shares | Current |
---|---|
Total value | 12.04 bn |
Total shares | 25.24 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Jonathan M Rothberg | 6.87 mm | $5.49 mm |
HealthCor Management | 3.88 mm | $3.26 bn |
HC Sponsor | 3.38 mm | $0.00 |
Security Benefit Life Insurance | 2.47 mm | $2.07 bn |
FOSUF Fosun International | 1.74 mm | $1.46 bn |
Avidity Partners Management | 1.50 mm | $1.26 bn |
GOOG Alphabet | 898.72 k | $754.93 mm |
Alyeska Investment | 750.00 k | $630.00 mm |
BLK Blackrock | 689.20 k | $578.92 mm |
Vanguard | 587.50 k | $493.50 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
16 Feb 23 | Alok Gupta | Class A Common Stock | Sell | Dispose S | No | No | 1.39 | 5,613 | 7.80 k | 110,456 |
16 Feb 23 | Khan Siddiqui | Class A Common Stock | Sell | Dispose S | No | No | 1.39 | 4,635 | 6.44 k | 80,445 |
13 Feb 23 | Brett Hale | Stock Option Class A Common Stock | Grant | Acquire A | No | No | 1.23 | 1,000,000 | 1.23 mm | 1,000,000 |
14 Dec 22 | Sainz Maria | Class A Common Stock | Buy | Acquire P | No | No | 0.95 | 5,000 | 4.75 k | 39,425 |
News
B. Riley Securities Maintains Buy on Hyperfine, Lowers Price Target to $2.5
22 Mar 23
Hyperfine Q4 EPS $(0.19) Beats $(0.22) Estimate, Sales $1.42M Miss $2.25M Estimate
21 Mar 23
Earnings Scheduled For March 21, 2023
21 Mar 23
Hyperfine's Earnings: A Preview
20 Mar 23
Why Provention Bio Shares Are Trading Higher By Over 260%; Here Are 20 Stocks Moving Premarket
13 Mar 23
Press releases
Hyperfine, Inc. Reports Fourth Quarter and Full Year 2022 Financial Results
21 Mar 23
Hyperfine, Inc. to Announce Fourth Quarter and Full Year 2022 Financial Results on March 21, 2023
6 Mar 23
Hyperfine, Inc. Receives FDA Clearance for Updated Software to Further Improve Diffusion-Weighted Imaging
28 Feb 23
Hyperfine, Inc. Swoop® Portable MR Imaging® System Receives CE Marking After Meeting Comprehensive New EU MDR Regulations
21 Feb 23
Hyperfine, Inc. Announces FDA Clearance for Improved AI-Powered Software and Expanded Field of View for the Swoop® Portable MR Imaging® System
13 Feb 23